China and US agree to extend trade tariff truce, says Li
SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology company currently valued at $968 million, recently sold a total of 4,000 shares of the company's common stock, according to an SEC filing. The transactions, executed on January 23 and 24, 2025, were carried out under a pre-established Rule 10b5-1 trading plan.
The shares were sold at prices ranging from $10.49 to $10.89, totaling $42,760. Following these sales, Ma Songjiang, through indirect ownership by a spouse, retains 2,899,138 shares in the company. According to InvestingPro analysis, GYRE's stock is currently trading above its Fair Value, with the company showing a FAIR overall financial health score despite not being profitable over the last twelve months.
These transactions were part of a larger strategy and executed in multiple trades. The weighted average prices for the sales were calculated with the shares sold at various prices between $10.42 and $11.21, as noted in the filing's footnotes. The stock has declined 7.5% year-to-date, while maintaining strong liquidity with a current ratio of 3.72. Get access to 6 more key insights about GYRE with an InvestingPro subscription.
In other recent news, Gyre Therapeutics has announced key changes within its leadership structure. The biotechnology firm recently appointed Ping Zhang as the lead independent director of its Board of Directors. Zhang, known for his strong financial background, will also serve on the Nominating and Corporate Governance Committee.
Simultaneously, Gyre Therapeutics reported changes at its indirectly owned subsidiary, Gyre Pharmaceuticals. Ying Luo has stepped down as Chairman, making room for Songjiang Ma to assume the role. These developments are part of recent events at the company.
Zhang's impressive career includes his current role as a Managing Partner at String Capital Management and previous positions at AEON Life Insurance (NSE:LIFI) Company and Japan Asia Investment Co. His academic achievements include a B.S. from Fudan University and an M.B.A. from the University of Chicago Booth School of Business.
Gyre Therapeutics is also focused on the development and commercialization of its drug F351 (Hydronidone) for MASH-associated fibrosis. Its subsidiary, Gyre Pharmaceuticals, has been progressing its pipeline in the People's Republic of China, including clinical trials for F351 and the commercialization of ETUARY® (Pirfenidone capsule). The company reported total revenues of $105.03 million in the last twelve months, with a gross profit margin of 96.23%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.